Matthew E. Garth - 30 May 2025 Form 4 Insider Report for DENTSPLY SIRONA Inc. (XRAY)

Reporting relationship: EVP & CFO
Issuer ticker: XRAY
Reported as of: 30 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jun 2025, 16:48:31 UTC
Prior SEC filing: 12 Dec 2024
Next SEC filing: 15 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Jessica Causey, Attorney-in-Fact for Matthew E. Garth

Key filing fact

Matthew E. Garth filed Form 4 for DENTSPLY SIRONA Inc. (XRAY) on 03 Jun 2025.

Key facts

This page summarizes Matthew E. Garth's Form 4 filing for DENTSPLY SIRONA Inc. (XRAY).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Jun 2025, 16:48.

Change

Previous filing in this sequence was filed on 12 Dec 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001695300 Primary reporting owner

GARTH MATTHEW E

Relationship: EVP & CFO
Address: C/O DENTSPLY SIRONA INC, 13320-B BALLANTYNE CORPORATE PLACE, CHARLOTTE
Signature: /s/ Jessica Causey, Attorney-in-Fact for Matthew E. Garth
Signature date: 03 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XRAY transaction

Common Stock

Award

Transaction value: $0
Shares: +43,023
Change %
Price: $0.000000
Shares after: 43,023
Date: 30 May 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XRAY transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +173,800
Change %
Price: $0.000000
Shares after: 173,800
Date: 30 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 173,800
Exercise price: $15.98
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Award consists entirely of Restricted Stock Units (RSUs) which vest in annual one-third (1/3) increments over a three-year period ending May 30, 2028.

Footnote F2

Stock Options vest in annual one-third (1/3) increments over a three-year period ending May 30, 2028.